As of May 29
| +0.07 / +0.74%|
The 7 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 12.50, with a high estimate of 16.00 and a low estimate of 5.00. The median estimate represents a +30.62% increase from the last price of 9.57.
The current consensus among 7 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.